Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry.
- DOI
- 10.1093/ibd/izag045
- Published
- 2026 Aug 1
- Container
- Inflammatory bowel diseases
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1093/ibd/izag045,
title = {Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry.},
author = {Verleye LMM and Pierik MJ and de Vries AC and van Schaik FDM and van der Meulen-de Jong AE and van Dop WA and Löwenberg M and Visschedijk MC and Naber MR and Bouwknegt DG and Römkens TEH and Bodelier AGL and Voorneveld PW and Oldenburg B and Derikx LAAP and Duijvestein M and Mujagić Z and Dutch Initiative on Crohn and Colitis (ICC)},
year = {2026},
journal = {Inflammatory bowel diseases},
doi = {10.1093/ibd/izag045},
url = {https://doi.org/10.1093/ibd/izag045}
}RIS
TY - JOUR TI - Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry. AU - Verleye LMM AU - Pierik MJ AU - de Vries AC AU - van Schaik FDM AU - van der Meulen-de Jong AE AU - van Dop WA AU - Löwenberg M AU - Visschedijk MC AU - Naber MR AU - Bouwknegt DG AU - Römkens TEH AU - Bodelier AGL AU - Voorneveld PW AU - Oldenburg B AU - Derikx LAAP AU - Duijvestein M AU - Mujagić Z AU - Dutch Initiative on Crohn and Colitis (ICC) PY - 2026 JO - Inflammatory bowel diseases DO - 10.1093/ibd/izag045 UR - https://doi.org/10.1093/ibd/izag045 ER -
APA
LMM, V., MJ, P., AC, D. V., FDM, V. S., AE, V. D. M. J., WA, V. D., M, L., MC, V., MR, N., DG, B., TEH, R., AGL, B., PW, V., B, O., LAAP, D., M, D., Z, M., & (ICC), D. I. O. C. A. C. (2026). Prospective real-world experience with risankizumab in difficult-to-treat Crohn's disease: results from the Dutch Initiative on Crohn and Colitis Registry.. Inflammatory bowel diseases. https://doi.org/10.1093/ibd/izag045
Source records
- pubmed · retrieved 2026-09-26T10:02:24.752Z